Abstract
Background: Cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors have been a significant breakthrough in the management of hormone receptor-positive, HER2......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
